Carvedilol: Solubilization and Cyclodextrin Complexation: A Technical Note

@article{Loftsson2008CarvedilolSA,
  title={Carvedilol: Solubilization and Cyclodextrin Complexation: A Technical Note},
  author={Thorsteinn Loftsson and Stine Byskov Vogensen and Cyrielle Desbos and Phatsawee Jansook},
  journal={AAPS PharmSciTech},
  year={2008},
  volume={9},
  pages={425-430}
}
Carvedilol (Table I) is a non-selective β-blocker indicated in the treatment of mild to moderate congestive heart failure. It also has vasodilating properties that are mainly attributed to its α1-blocking activity, as well as ability to inhibit oxidative stress in coronary smooth muscle (1). It is marketed under various trade names including Eucardic (Roche), Dilatrend (Roche), Kredex (Roche) and Coreg (GlaxoSmithKline). Carvedilol is well absorbed after oral administration, but is subject to… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 34 references

A second polymorph of carvedilol

  • H. S. Yathirajan, S. Bindya, T. V. Sreevidya, B. Narayana, M. Bolte
  • Acta Cryst. E63:o542–
  • 2007

Cyclodextrincontaining poly(ethyleneoxide) tablets for the delivery of poorly soluble drugs: Potential as buccal delivery system

  • B. Cappello, G. De Rosa, L. Giannini
  • Int. J. Pharm
  • 2006

Similar Papers

Loading similar papers…